Hugon J - Search Results

1

mTOR-dependent signalling in Alzheimer's disease.

Pei JJ, Hugon J. Pei JJ, et al. Among authors: hugon j. J Cell Mol Med. 2008 Dec;12(6B):2525-32. doi: 10.1111/j.1582-4934.2008.00509.x. J Cell Mol Med. 2008. PMID: 19210753 Free PMC article. Review.

2

mTOR/p70S6k signalling alteration by Abeta exposure as well as in APP-PS1 transgenic models and in patients with Alzheimer's disease.

Lafay-Chebassier C, Paccalin M, Page G, Barc-Pain S, Perault-Pochat MC, Gil R, Pradier L, Hugon J. Lafay-Chebassier C, et al. Among authors: hugon j. J Neurochem. 2005 Jul;94(1):215-25. doi: 10.1111/j.1471-4159.2005.03187.x. J Neurochem. 2005. PMID: 15953364 Free article.

3

Activated mTOR and PKR kinases in lymphocytes correlate with memory and cognitive decline in Alzheimer's disease.

Paccalin M, Pain-Barc S, Pluchon C, Paul C, Besson MN, Carret-Rebillat AS, Rioux-Bilan A, Gil R, Hugon J. Paccalin M, et al. Among authors: hugon j. Dement Geriatr Cogn Disord. 2006;22(4):320-6. doi: 10.1159/000095562. Epub 2006 Sep 4. Dement Geriatr Cogn Disord. 2006. PMID: 16954686

4

Biomarkers in Sporadic and Familial Alzheimer's Disease.

Lista S, O'Bryant SE, Blennow K, Dubois B, Hugon J, Zetterberg H, Hampel H. Lista S, et al. Among authors: hugon j. J Alzheimers Dis. 2015;47(2):291-317. doi: 10.3233/JAD-143006. J Alzheimers Dis. 2015. PMID: 26401553 Review.

5

The PKR/P38/RIPK1 Signaling Pathway as a Therapeutic Target in Alzheimer's Disease.

Hugon J, Paquet C. Hugon J, et al. Int J Mol Sci. 2021 Mar 19;22(6):3136. doi: 10.3390/ijms22063136. Int J Mol Sci. 2021. PMID: 33808629 Free PMC article. Review.

6

Phosphorylation of eukaryotic initiation factor-2alpha (eIF2alpha) is associated with neuronal degeneration in Alzheimer's disease.

Chang RC, Wong AK, Ng HK, Hugon J. Chang RC, et al. Among authors: hugon j. Neuroreport. 2002 Dec 20;13(18):2429-32. doi: 10.1097/00001756-200212200-00011. Neuroreport. 2002. PMID: 12499843

7

Dissociation of Akt/PKB and ribosomal S6 kinase signaling markers in a transgenic mouse model of Alzheimer's disease.

Damjanac M, Rioux Bilan A, Paccalin M, Pontcharraud R, Fauconneau B, Hugon J, Page G. Damjanac M, et al. Among authors: hugon j. Neurobiol Dis. 2008 Feb;29(2):354-67. doi: 10.1016/j.nbd.2007.09.008. Epub 2007 Oct 11. Neurobiol Dis. 2008. PMID: 18023354

8

[Molecular and therapeutic approaches of the Alzheimer's disease].

Hugon J, Paquet C. Hugon J, et al. Morphologie. 2007 Dec;91(295):221-5. doi: 10.1016/j.morpho.2007.10.012. Epub 2007 Nov 28. Morphologie. 2007. PMID: 18054263 French.

9

Targeting miRNAs in Alzheimer's disease.

Hugon J, Paquet C. Hugon J, et al. Expert Rev Neurother. 2008 Nov;8(11):1615-6. doi: 10.1586/14737175.8.11.1615. Expert Rev Neurother. 2008. PMID: 18986230 Review. No abstract available.

10

PKR, a cognitive decline biomarker, can regulate translation via two consecutive molecular targets p53 and Redd1 in lymphocytes of AD patients.

Damjanac M, Page G, Ragot S, Laborie G, Gil R, Hugon J, Paccalin M. Damjanac M, et al. Among authors: hugon j. J Cell Mol Med. 2009 Aug;13(8B):1823-1832. doi: 10.1111/j.1582-4934.2009.00688.x. Epub 2009 Feb 4. J Cell Mol Med. 2009. PMID: 19210572 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

470 results

Search Page